UCB (OTCMKTS:UCBJY) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

UCB SA (OTCMKTS:UCBJY)’s share price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $143.82 and traded as low as $134.94. UCB shares last traded at $134.94, with a volume of 36,592 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on UCBJY shares. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Jefferies Financial Group raised UCB to a “moderate sell” rating in a report on Monday, June 22nd. Finally, Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, UCB currently has an average rating of “Hold”.

UCB Stock Performance

The company’s fifty day moving average price is $143.82 and its two-hundred day moving average price is $147.85. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.